PL2387395T3 - Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym - Google Patents
Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowymInfo
- Publication number
- PL2387395T3 PL2387395T3 PL10700686T PL10700686T PL2387395T3 PL 2387395 T3 PL2387395 T3 PL 2387395T3 PL 10700686 T PL10700686 T PL 10700686T PL 10700686 T PL10700686 T PL 10700686T PL 2387395 T3 PL2387395 T3 PL 2387395T3
- Authority
- PL
- Poland
- Prior art keywords
- treating
- preventing
- combination therapy
- metastatic cancer
- axl inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14544809P | 2009-01-16 | 2009-01-16 | |
| PCT/US2010/021275 WO2010083465A1 (en) | 2009-01-16 | 2010-01-15 | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
| EP10700686.8A EP2387395B1 (en) | 2009-01-16 | 2010-01-15 | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2387395T3 true PL2387395T3 (pl) | 2015-03-31 |
Family
ID=41683427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10700686T PL2387395T3 (pl) | 2009-01-16 | 2010-01-15 | Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US8546433B2 (enExample) |
| EP (1) | EP2387395B1 (enExample) |
| JP (2) | JP5858789B2 (enExample) |
| CN (1) | CN102281875B (enExample) |
| AU (1) | AU2010204578B2 (enExample) |
| BR (1) | BRPI1007046B1 (enExample) |
| CA (1) | CA2749843C (enExample) |
| ES (1) | ES2528032T3 (enExample) |
| PL (1) | PL2387395T3 (enExample) |
| PT (1) | PT2387395E (enExample) |
| RU (1) | RU2555326C2 (enExample) |
| SG (1) | SG172997A1 (enExample) |
| WO (1) | WO2010083465A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2621503C (en) * | 2005-09-07 | 2014-05-20 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
| CA2710230C (en) | 2006-12-29 | 2016-02-23 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| RS53281B (sr) | 2006-12-29 | 2014-08-29 | Rigel Pharmaceuticals Inc. | Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori |
| CN101622248B (zh) | 2006-12-29 | 2013-04-17 | 里格尔制药公司 | 用作axl抑制剂的n3-杂芳基取代的三唑和n5-杂芳基取代的三唑 |
| ES2406930T3 (es) | 2006-12-29 | 2013-06-10 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL |
| CA2710051C (en) | 2006-12-29 | 2017-05-16 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
| CA2704052C (en) * | 2007-10-26 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| HRP20170317T1 (hr) | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| CA2730251C (en) | 2008-07-09 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| CA2730231C (en) | 2008-07-09 | 2016-10-18 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| JP4644273B2 (ja) * | 2008-07-15 | 2011-03-02 | 本田技研工業株式会社 | 車両周辺監視装置 |
| BRPI1007046B1 (pt) | 2009-01-16 | 2019-07-16 | Rigel Pharmaceuticals, Inc. | Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático. |
| EP2484678B1 (en) | 2009-09-28 | 2015-01-21 | Qilu Pharmaceutical Co., Ltd | 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors |
| GB201207722D0 (en) | 2012-05-02 | 2012-06-13 | Bergenbio As | Method |
| WO2014018535A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| AU2014353006B2 (en) | 2013-11-20 | 2019-04-04 | Signalchem Life Sciences Corp. | Quinazoline derivatives as TAM family kinase inhibitors |
| JP6496731B2 (ja) | 2013-11-27 | 2019-04-03 | シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体 |
| US9801880B2 (en) | 2013-12-02 | 2017-10-31 | Bergenbio As | Use of kinase inhibitors |
| US20170027940A1 (en) * | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015161230A1 (en) * | 2014-04-19 | 2015-10-22 | Massachusetts Institute Of Technology | Methods of reducing kinase inhibitor resistance |
| GB201420285D0 (en) | 2014-11-14 | 2014-12-31 | Bergenbio As | Process |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| CN106083764B (zh) * | 2016-07-11 | 2018-09-18 | 上海皓元生物医药科技有限公司 | 一种用于制备axl抑制剂的高纯度中间体的手性拆分方法 |
| CN109384774B (zh) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用 |
| EP3703731A4 (en) * | 2017-11-04 | 2021-07-21 | Aravive Biologics, Inc. | METHOD OF TREATMENT OF METASTATIC CANCER USING AXL DECOY RECEPTORS |
| TWI824010B (zh) | 2018-09-18 | 2023-12-01 | 加拿大商聖諾康生命科學公司 | 治療血癌之組合療法 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| WO2022220227A1 (ja) * | 2021-04-14 | 2022-10-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | テトラヒドロピリドピリミジン化合物 |
| GB202209285D0 (en) | 2022-06-24 | 2022-08-10 | Bergenbio Asa | Dosage regimen for AXL inhibitor |
| AR129722A1 (es) | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1403866A (en) | 1971-12-06 | 1975-08-28 | Wyeth John & Brother Ltd | Derivatives of 3-amino-1,2,4-triazoles |
| US4512992A (en) | 1980-06-13 | 1985-04-23 | Burroughs Wellcome Co. | Treatment with dialkoxy pyridopyrimidine compounds |
| WO1990007926A1 (en) | 1989-01-20 | 1990-07-26 | Pfizer Inc. | 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines |
| US6258360B1 (en) | 1989-05-04 | 2001-07-10 | Igen International, Inc. | Prodrugs activated by targeted catalytic proteins |
| EP0710654A4 (en) | 1993-07-23 | 1996-08-28 | Green Cross Corp | TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE |
| UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| GB9918180D0 (en) | 1999-08-02 | 1999-10-06 | Smithkline Beecham Plc | Novel compositions |
| NZ526624A (en) | 2000-12-22 | 2005-07-29 | Ortho Mcneil Pharm Inc | Substituted triazole diamine derivatives as kinase inhibitors |
| DE10123586A1 (de) | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
| TW201041580A (en) | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| NZ535349A (en) | 2002-03-08 | 2007-01-26 | Signal Pharm Inc | JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular |
| MXPA04010778A (es) | 2002-05-03 | 2005-03-07 | Janssen Pharmaceutica Nv | Microemulsiones polimericas. |
| US20060293256A1 (en) | 2002-08-06 | 2006-12-28 | Masateru Yamada | Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| EP1563094A4 (en) | 2002-10-29 | 2007-04-25 | Rigel Pharmaceuticals Inc | MODULATORS OF ANGIOGENESIS AND TUMORIGENESIS |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| AU2004220176A1 (en) | 2003-03-14 | 2004-09-23 | Astrazeneca Ab | Novel fused triazolones and the uses thereof |
| AU2004247559B2 (en) | 2003-06-12 | 2009-08-27 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
| ATE455546T1 (de) | 2003-08-06 | 2010-02-15 | Vertex Pharma | Aminotriazol-verbindungen als proteinkinase- hemmer |
| CN1934107A (zh) | 2004-01-30 | 2007-03-21 | Ab科学公司 | 作为酪氨酸激酶抑制剂的2－(3－取代芳基)氨基－4－芳基－噻唑 |
| WO2005077922A2 (en) | 2004-02-11 | 2005-08-25 | Janssen Pharmaceutica, N.V. | Process for the preparation of substituted triazole compounds |
| JP4812763B2 (ja) | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途 |
| BRPI0515012A (pt) | 2004-08-13 | 2008-07-01 | Genentech Inc | substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso |
| PT1791830E (pt) | 2004-09-17 | 2011-04-04 | Vertex Pharma | Compostos de diaminotriazole úteis como inibidores de proteína-quinase |
| PL1811998T3 (pl) | 2004-10-21 | 2011-05-31 | Vertex Pharma | Triazole użyteczne jako inhibitory kinaz białkowych |
| US20060166936A1 (en) | 2004-10-29 | 2006-07-27 | Hayley Binch | Diaminotriazole compounds useful as inhibitors of protein kinases |
| RU2007123675A (ru) | 2004-11-24 | 2008-12-27 | Новартис АГ (CH) | Комбинации ингибиторов jak |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| CA2621503C (en) | 2005-09-07 | 2014-05-20 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
| EP1960372B1 (en) | 2005-12-15 | 2015-12-09 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
| EP2007393B1 (en) | 2006-04-07 | 2013-08-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
| US8097630B2 (en) | 2006-10-10 | 2012-01-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors |
| FR2908131B1 (fr) | 2006-11-03 | 2009-01-09 | Univ Haute Alsace Etablissemen | Derives d'aminobenzocycloheptene,leurs procedes de preparation et leur utilisation en therapeutique |
| JP2008130120A (ja) | 2006-11-17 | 2008-06-05 | Sharp Corp | 光ピックアップ装置 |
| WO2008080134A2 (en) | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors |
| CA2710230C (en) | 2006-12-29 | 2016-02-23 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| RS53281B (sr) | 2006-12-29 | 2014-08-29 | Rigel Pharmaceuticals Inc. | Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori |
| CA2710051C (en) | 2006-12-29 | 2017-05-16 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
| CN101622248B (zh) | 2006-12-29 | 2013-04-17 | 里格尔制药公司 | 用作axl抑制剂的n3-杂芳基取代的三唑和n5-杂芳基取代的三唑 |
| ES2406930T3 (es) | 2006-12-29 | 2013-06-10 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL |
| BRPI0813356A2 (pt) | 2007-06-15 | 2014-12-30 | Irm Llc | Inibidores de proteína quinase e métodos para uso dos mesmos |
| CA2704052C (en) | 2007-10-26 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| HRP20170317T1 (hr) | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| CA2730251C (en) | 2008-07-09 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| CA2730231C (en) | 2008-07-09 | 2016-10-18 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| BRPI1007046B1 (pt) * | 2009-01-16 | 2019-07-16 | Rigel Pharmaceuticals, Inc. | Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático. |
-
2010
- 2010-01-15 BR BRPI1007046-0A patent/BRPI1007046B1/pt active IP Right Grant
- 2010-01-15 ES ES10700686.8T patent/ES2528032T3/es active Active
- 2010-01-15 AU AU2010204578A patent/AU2010204578B2/en active Active
- 2010-01-15 JP JP2011546409A patent/JP5858789B2/ja active Active
- 2010-01-15 PT PT107006868T patent/PT2387395E/pt unknown
- 2010-01-15 SG SG2011051174A patent/SG172997A1/en unknown
- 2010-01-15 RU RU2011132118/15A patent/RU2555326C2/ru active
- 2010-01-15 US US12/688,746 patent/US8546433B2/en active Active
- 2010-01-15 EP EP10700686.8A patent/EP2387395B1/en active Active
- 2010-01-15 CA CA2749843A patent/CA2749843C/en active Active
- 2010-01-15 PL PL10700686T patent/PL2387395T3/pl unknown
- 2010-01-15 WO PCT/US2010/021275 patent/WO2010083465A1/en not_active Ceased
- 2010-01-15 CN CN201080004818.0A patent/CN102281875B/zh active Active
-
2013
- 2013-06-03 US US13/908,874 patent/US20130338161A1/en not_active Abandoned
-
2014
- 2014-10-10 JP JP2014208912A patent/JP2015007135A/ja active Pending
-
2016
- 2016-03-22 US US15/077,648 patent/US20170042891A1/en not_active Abandoned
-
2019
- 2019-03-12 US US16/351,130 patent/US20190336500A1/en not_active Abandoned
-
2021
- 2021-06-18 US US17/351,996 patent/US20210379064A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT2387395E (pt) | 2015-02-04 |
| AU2010204578B2 (en) | 2016-05-12 |
| JP2015007135A (ja) | 2015-01-15 |
| US20190336500A1 (en) | 2019-11-07 |
| US20210379064A1 (en) | 2021-12-09 |
| CN102281875B (zh) | 2017-09-22 |
| HK1164146A1 (en) | 2012-09-21 |
| ES2528032T3 (es) | 2015-02-03 |
| EP2387395B1 (en) | 2014-10-15 |
| JP5858789B2 (ja) | 2016-02-10 |
| AU2010204578A1 (en) | 2011-07-28 |
| JP2012515225A (ja) | 2012-07-05 |
| RU2555326C2 (ru) | 2015-07-10 |
| BRPI1007046A2 (pt) | 2015-07-21 |
| CN102281875A (zh) | 2011-12-14 |
| US20130338161A1 (en) | 2013-12-19 |
| CA2749843C (en) | 2017-09-05 |
| RU2011132118A (ru) | 2013-02-27 |
| SG172997A1 (en) | 2011-08-29 |
| US20100196511A1 (en) | 2010-08-05 |
| EP2387395A1 (en) | 2011-11-23 |
| BRPI1007046B1 (pt) | 2019-07-16 |
| US8546433B2 (en) | 2013-10-01 |
| WO2010083465A1 (en) | 2010-07-22 |
| CA2749843A1 (en) | 2011-07-22 |
| US20170042891A1 (en) | 2017-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2387395E (pt) | Inibidores de axl para utilização em terapia de combinação para prevenir, tratar ou gerir cancro metastático | |
| IL219992A0 (en) | Combination therapy for treating cancer and dianostic assays for use therein | |
| ZA200906765B (en) | Combination therapies comprising quinoxaline inhibitors of P13K-Alpha for use in the treatment of cancer | |
| IL200186A0 (en) | Activin-actriia antagonists and uses for treating or preventing breast cancer | |
| PL2427441T3 (pl) | Aktywatory PKM2 do stosowania w leczeniu raka | |
| LT2556071T (lt) | Kinazės inhibitoriai ir jų panaudojimas vėžio gydymui | |
| IL218316A (en) | Use of tiny taxane-containing particles to treat cancer in combination with hedgehog inhibitors | |
| PL2358697T3 (pl) | Związki izoindolinowe do zastosowania w leczeniu raka | |
| GB0921596D0 (en) | Particles for the treatment of cancer in combination with radiotherapy | |
| ZA201008140B (en) | Treatment of metastatic tumors | |
| PT2101731T (pt) | Endoxifeno para utilização no tratamento de cancro | |
| IL207212A0 (en) | 4-pyridinone compounds and their use for cancer | |
| IL218182A0 (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy | |
| ZA201203325B (en) | Methods and compositions for treating solid tumors and other malignancies | |
| IL202307A0 (en) | Multikinase inhibitors for use in the treatment of cancer | |
| GB0804496D0 (en) | Treating cancer | |
| EP2144888A4 (en) | METHODS OF TREATING CANCER | |
| IL199911A0 (en) | 3-cinnolinecarboxamide derivatives and their use for treating cancer | |
| EP2137213A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER | |
| EP2374463A4 (en) | COMPOSITION FOR IMPROVING RADIATION THERAPY FOR CANCER | |
| IL206189A (en) | Compounds for use in cancer treatment | |
| GB0707556D0 (en) | Treatment for cancer | |
| ZA201201894B (en) | Pharmaceutical combination for treating tumor | |
| AP2011005893A0 (en) | Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer. | |
| GB0809046D0 (en) | Cancer treatment |